{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:03Z","timestamp":1787020143106,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alberta Health Services Critical Care Strategic Clinical Network"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prescribing trends suggest that pharmacologic alternatives to antipsychotics are gaining in popularity, but randomized trial (RCT) data of their comparative safety is scarce. Our objective was to describe the comparative safety of pharmacologic interventions for treating neuropsychiatric symptoms in dementia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched MEDLINE, EMBASE, CENTRAL, CINAHL, and PsycINFO, from inception to May 28, 2019, for studies of pharmacologic interventions used to treat neuropsychiatric symptoms in dementia. Dementia care partners selected fracture risk as our primary outcome. Pairs of reviewers, working independently, conducted all study screening, data abstraction, and risk of bias appraisal. We conducted Bayesian random-effects network meta-analyses (NMAs) using data from RCTs to derive odds ratios (ORs). In secondary analyses, we conducted frequentist random-effects NMAs using data from RCTs and Bayesian three-level hierarchical random-effects NMAs incorporating data from RCTs and non-randomized studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our systematic review included 209 randomized and non-randomized studies (889,378 persons with dementia). In NMAs of data from randomized trials, there were no increased odds of fracture associated with any intervention in primary analyses; however, data were sparse. We found increased odds of cerebrovascular events associated with antipsychotics (odds ratio [OR] 2.12, 95% credible interval [CrI] 1.29 to 3.62; number needed to harm [NNH]\u2009=\u200999) and increased odds of falls associated with dextromethorphan-quinidine (OR 4.16, 95% CrI 1.47 to 14.22; NNH\u2009=\u200955) compared to placebo in persons with dementia. In a subgroup of persons with Alzheimer disease, antipsychotics were associated with increased odds of fracture compared to anticonvulsants (OR 54.1, 95% CrI 1.15 to 38,300; NNH\u2009=\u200918). In older persons (mean age\u2009\u2265\u200980\u2009years) with dementia, anticonvulsants were associated with increased odds of death compared to placebo (OR 8.36, 95% CrI 1.17 to 203.4; NNH\u2009=\u200935) and antipsychotics were associated with increased odds of death compared to antidepressants (OR 5.28, 95% CrI 1.06 to 3.51; NNH\u2009=\u200947).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Although antipsychotics were associated with greater harm than antidepressants and anticonvulsants in subgroups of persons with dementia, medications used\n                      <jats:italic>in lieu<\/jats:italic>\n                      of antipsychotics for treating neuropsychiatric symptoms in dementia, such as anticonvulsants and dextromethorphan-quinidine, were also associated with harm. Decision-making concerning treatments prescribed\n                      <jats:italic>in lieu<\/jats:italic>\n                      of antipsychotics should include potential harms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration<\/jats:title>\n                    <jats:p>CRD42017050130.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12877-020-01607-7","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T09:03:45Z","timestamp":1592298225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Jennifer A.","family":"Watt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areti Angeliki","family":"Veroniki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Nincic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ghassemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonda","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Treister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea C.","family":"Tricco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"1607_CR1","unstructured":"Patterson C. World Alzheimer Report 2018 - The state of the art of dementia research: New frontiers. London: Alzheimer\u2019s Disease International; 2018."},{"issue":"7496","key":"1607_CR2","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","volume":"330","author":"C Ballard","year":"2005","unstructured":"Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330(7496):874.","journal-title":"BMJ."},{"key":"1607_CR3","first-page":"21","volume":"7","author":"L Buettner","year":"1998","unstructured":"Buettner L, Ferrario J. Therapeutic recreation-nursing team: a therapeutic intervention for nursing home residents with dementia. Ann Ther Recreation. 1998;7:21\u20138.","journal-title":"Ann Ther Recreation"},{"issue":"9","key":"1607_CR4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1017\/S1041610211000743","volume":"23","author":"Y Barak","year":"2011","unstructured":"Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. Int Psychogeriatr. 2011;23(9):1515\u20139.","journal-title":"Int Psychogeriatr"},{"key":"1607_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","volume":"146","author":"SS Gill","year":"2007","unstructured":"Gill SS, Bronskill SE, Normand S-LT, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775\u201386.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1607_CR6","first-page":"1269","volume":"167","author":"E Wooltorton","year":"2002","unstructured":"Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Can Med Assoc J. 2002;167(11):1269\u201370.","journal-title":"Can Med Assoc J"},{"key":"1607_CR7","first-page":"17","volume":"64","author":"LM Bjerre","year":"2018","unstructured":"Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia. Can Fam Physician. 2018;64:17\u201327.","journal-title":"Can Fam Physician"},{"issue":"11","key":"1607_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"1607_CR9","volume-title":"Ten Things Clinicians and Patients Should Question. Choosing Wisely","author":"American Geriatrics Society","year":"2015","unstructured":"American Geriatrics Society: Ten Things Clinicians and Patients Should Question. Choosing Wisely; 2015."},{"issue":"9","key":"1607_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.7326\/M19-0993","volume":"171","author":"JA Watt","year":"2019","unstructured":"Watt JA, Goodarzi Z, Veroniki AA, Nincic V, Khan PA, Ghassemi M, et al. Comparative efficacy of interventions for aggressive and agitated behaviors in dementia: a systematic review and network meta-analysis. Ann Intern Med. 2019;171(9):633\u201342.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1607_CR11","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jamda.2019.05.022","volume":"20","author":"HC Kales","year":"2019","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. When less is more, but still not enough: why focusing on limiting antipsychotics in people with dementia is the wrong policy imperative. J Am Med Dir Assoc. 2019;20(9):1074\u20139.","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"1607_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jamda.2011.07.006","volume":"13","author":"J Cohen-Mansfield","year":"2012","unstructured":"Cohen-Mansfield J, Thein K, Marx MS, Dakheel-Ali M. What are the barriers to performing nonpharmacological interventions for behavioral symptoms in the nursing home? J Am Med Dir Assoc. 2012;13(4):400\u20135.","journal-title":"J Am Med Dir Assoc"},{"key":"1607_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40266-016-0380-3","volume":"33","author":"A Iaboni","year":"2016","unstructured":"Iaboni A, Bronskill SE, Reynolds KB, Wang X, Rochon PA, Herrmann N, et al. Changing pattern of sedative use in older adults: a population-based cohort study. Drugs Aging. 2016;33:523\u201333.","journal-title":"Drugs Aging"},{"issue":"182","key":"1607_CR14","first-page":"1","volume":"6","author":"J Watt","year":"2017","unstructured":"Watt J, Goodarzi Z, Tricco AC, Veroniki A-A, Straus SE. Comparative safety and efficacy of pharmacological and non-pharmacological interventions for the behavioral and psychological symptoms of dementia: protocol for a systematic review and network meta-analysis. Syst Rev. 2017;6(182):1\u20139.","journal-title":"Syst Rev"},{"issue":"47","key":"1607_CR15","doi-asserted-by":"publisher","first-page":"E1376","DOI":"10.1503\/cmaj.180551","volume":"190","author":"JA Watt","year":"2018","unstructured":"Watt JA, Gomes T, Bronskill SE, Huang A, Austin PC, Ho JM, et al. Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study. CMAJ. 2018;190(47):E1376\u2013E83.","journal-title":"CMAJ."},{"key":"1607_CR16","volume-title":"2015 Guideline explanation and elaboration (PRESS E&E). Ottawa","author":"PRESS-Peer Review of Electronic Search Strategies","year":"2016","unstructured":"PRESS-Peer Review of Electronic Search Strategies: 2015 Guideline explanation and elaboration (PRESS E&E). Ottawa; 2016."},{"key":"1607_CR17","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration; 2011. Available from: www.handbook.cochrane.org."},{"key":"1607_CR18","unstructured":"Wells GA, Gu J, Singla N, Chung F, Pearman MH, Bergese SD. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses2008. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"1607_CR19","unstructured":"EPOC Risk of bias tool 2011 [Available from: http:\/\/epoc.cochrane.org\/sites\/epoc.cochrane.org\/files\/uploads\/Risk%20of%20Bias%2005-01-2009.doc."},{"issue":"10","key":"1607_CR20","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.","journal-title":"PLoS One"},{"key":"1607_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise nad network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33:607\u201317.","journal-title":"Med Decis Mak"},{"issue":"3","key":"1607_CR22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic reviews. Int J Epidemiol. 2012;41(3):818\u201327.","journal-title":"Int J Epidemiol"},{"key":"1607_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jclinepi.2016.02.016","volume":"76","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Straus S, Fyraridis A, Tricco AC. The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes. J Clin Epidemiol. 2016;76:193\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1607_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dys222","volume":"42","author":"AA Veroniki","year":"2013","unstructured":"Veroniki AA, Vasiliadis HS, Higgins JPT, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42:332\u201345.","journal-title":"Int J Epidemiol"},{"key":"1607_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JPT Higgins","year":"2012","unstructured":"Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3:98\u2013110.","journal-title":"Res Synth Methods"},{"issue":"1","key":"1607_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12916-016-0764-6","volume":"15","author":"W Zarin","year":"2017","unstructured":"Zarin W, Veroniki AA, Nincic V, Vafaei A, Reynen E, Motiwala SS, et al. Characteristics and knowledge synthesis approach for 456 network meta-analyses: a scoping review. BMC Med. 2017;15(1):3.","journal-title":"BMC Med"},{"key":"1607_CR27","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1002\/sim.5764","volume":"32","author":"S Schmitz","year":"2013","unstructured":"Schmitz S, Adams R, Walsh C. Incorporating data from various trial designs into a mixed treatment comparison model. Stat Med. 2013;32:2935\u201349.","journal-title":"Stat Med"},{"key":"1607_CR28","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1002\/sim.2112","volume":"24","author":"PC Lambert","year":"2005","unstructured":"Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med. 2005;24:2401\u201328.","journal-title":"Stat Med"},{"key":"1607_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0895-4356(02)00443-2","volume":"55","author":"MJ Symons","year":"2002","unstructured":"Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol. 2002;55:893\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"1607_CR30","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1007\/s00415-019-09200-8","volume":"266","author":"B Jin","year":"2019","unstructured":"Jin B, Liu H. Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis. J Neurol. 2019;266(10):2363\u201375.","journal-title":"J Neurol"},{"issue":"3","key":"1607_CR31","doi-asserted-by":"publisher","first-page":"e190828","DOI":"10.1001\/jamanetworkopen.2019.0828","volume":"2","author":"I Yunusa","year":"2019","unstructured":"Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019;2(3):e190828.","journal-title":"JAMA Netw Open"},{"key":"1607_CR32","first-page":"391","volume":"10","author":"K Hager","year":"2014","unstructured":"Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatr Dis Treat. 2014;10:391\u2013401.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1607_CR33","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","volume":"288","author":"CG Lyketsos","year":"2002","unstructured":"Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475\u201383.","journal-title":"JAMA."}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-020-01607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-020-01607-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-020-01607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T19:16:30Z","timestamp":1623784590000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-020-01607-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1607"],"URL":"https:\/\/doi.org\/10.1186\/s12877-020-01607-7","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"30 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAW was supported by a Canadian Institutes of Health Research (CIHR) doctoral research award and the University of Toronto Department of Medicine Eliot Phillipson Clinician Scientist Training program during the completion of this manuscript. ACT is on the editorial board for BMC Medicine and funded by a Tier 2 Canada Research Chair in Knowledge Synthesis. SES is funded by a Tier 1 Canada Research Chair in Knowledge Translation. AAV is funded by a European Union\u2019s Horizon 2020 grant [No. 754936]. All other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}